Figure 4
![Figure 4. The survival benefit of a donor KIR B haplotype is not dependent on the presence of KIR2DS2. Donors with KIR B haplotypes were divided into 2 groups based on the presence (2DS2+, n = 252) or absence (2DS2−, n = 65) of KIR2DS2. Survival was significantly better for patients who received transplants from donors with either KIR B haplotype (2DS2+: 31% [95% CI: 25-37] or 2DS2−: 31% [95% CI: 20-42]) versus donors homozygous for the A haplotype (A/A: 20% [95% CI: 13-27]; P = .02).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/113/3/10.1182_blood-2008-07-171926/5/zh80020929410004.jpeg?Expires=1735537122&Signature=jC8QWdhj61Nl8E1jans4zdhC0uCyVvbwVKYEJGX-IsO3kXLrjYPMRrTrdLQzCSVuvPl1GR669is-lieKZWOdkurZ6D0q96gNe7L3p8YGZ8fvmaPa5IkDFIYaswermCky0DDNJOiSF8Uj1R7jW~NgMNxX-mjpV~gitkO3WqDjZf0N72ARbLTV9RXjdtmVBW0QuCCxERDb2-pI9klCQFRGIksiWMZbl2aKhwFD8ETYaJojmoWZli~2mna8xdus7bDM2sMWbTmRKyXbHrxl2M6YRG9DmTAElwpEuSBsxMg3sFSmouL2480--utE-AY-ySyWOc4sYzmUS99HLYKXzPNobw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The survival benefit of a donor KIR B haplotype is not dependent on the presence of KIR2DS2. Donors with KIR B haplotypes were divided into 2 groups based on the presence (2DS2+, n = 252) or absence (2DS2−, n = 65) of KIR2DS2. Survival was significantly better for patients who received transplants from donors with either KIR B haplotype (2DS2+: 31% [95% CI: 25-37] or 2DS2−: 31% [95% CI: 20-42]) versus donors homozygous for the A haplotype (A/A: 20% [95% CI: 13-27]; P = .02).
